|Day Low/High||13.21 / 13.80|
|52 Wk Low/High||4.41 / 14.05|
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
Big gains could be ahead for investors willing to stick with the stock, according to one firm.
Represents World's Second Largest Diagnosed Global Fabry Patient Population
Akari Therapeutics, Array BioPharma and Amicus Therapeutics were among the biotech movers in premarket trading on Wednesday.
Top-Line Data on Track for 3Q17
Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.
Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Amicus Therapeutics and Minerva Neurosciences were among the biotech movers in premarket trading on Monday.
In trading on Monday, shares of Amicus Therapeutics Inc crossed below their 200 day moving average of $6.78, changing hands as low as $6.73 per share. Amicus Therapeutics Inc shares are currently trading down about 1.7% on the day.
Three small-cap biotechs with attractive risk/reward profiles.
Investors in Amicus Therapeutics Inc saw new options become available this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new May 19th contracts and identified one put and one call contract of particular interest.
Ministry of Health Publishes Final Guidance Covering Reimbursement of Galafold for Fabry Disease
Absent specific policy details, Trump's speech leaves investors guessing about his real plans for the FDA and the drug approval process. He has not yet named an FDA commissioner.